The bill introduces the "Prescription Drug Sales Representative Disclosure Act," which requires pharmaceutical manufacturers to provide the Department of Business Regulation with a detailed and updated list of each pharmaceutical sales representative engaged by the manufacturer to market prescription drugs in the state. Manufacturers must inform the department of any changes to this list within 60 days and are required to refile or update the list annually. The department will provide electronic access to the most recent list to healthcare providers, pharmacies, and medical facilities to ensure compliance with the new regulations.

To enforce these requirements, the bill establishes an annual fee of $55 for each pharmaceutical sales representative listed by the manufacturer. It also outlines civil penalties for manufacturers that fail to provide the required information, with fines of up to $10,000 per violation. Each unlawful failure to provide information constitutes a separate violation. The act is set to take effect on January 1, 2026, aiming to enhance transparency and accountability in the marketing practices of pharmaceutical sales representatives.